NetworkNewsBreaks – BriaCell Therapeutics Corp.
Post# of 69
Immuno-oncology-focused biotechnology company BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) recently secured support for its novel immunotherapy clinical research in the form of an equity investment of C$500,000 by the company’s recently appointed director, Jamieson Bondarenko (http://nnw.fm/dW4iF). A recent article includes a comment from Bondarenko regarding the investment, where he states, “The importance of accelerating this work is evidenced in efficacy data of BriaCell’s Phase I/IIa study of Bria-IMT and safety data of the Bria-IMT KEYTRUDA combination study in advanced breast cancer. There exists a unique opportunity to advance BriaCell’s remarkable achievements on behalf of breast cancer patients, survivors and deceased, and their families.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer